Literature DB >> 14635042

Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross-reactive, natural HBsAg variants.

Reinhold Schirmbeck1, Nektarios Dikopoulos, Marcin Kwissa, Frank Leithäuser, Kasper Lamberth, Soren Buus, Karl Melber, Jörg Reimann.   

Abstract

Processing exogenous hepatitis B surface antigen (HBsAg) of the hepatitis B virus (HBV) generates the K(b)-binding S(208-215) epitope 1; processing endogenous HBsAg generates the K(b)-binding S(190-197) epitope 2. Cross-reactive CD8(+) T cell responses were primed to epitope 1 but not epitope 2 when mice were immunized with natural HBsAg(ayw), or HBsAg(adw2) variants differing within both epitopes by one or two residues. Expression of HBsAg(ayw) from a transgene in the liver renders (HBs-tg) mice tolerant to epitope 1 of HBsAg(ayw). CD8(+) T cells specific for epitope 1 could be primed in HBs-tg mice by HBsAg(adw2); these specific CD8(+) T cells cross-reacted with epitope 1 processed from the transgene-encoded HBsAg(ayw). The liver of vaccinated HBsAg(ayw) transgenic mice showed severe histopathology and contained functional (IFNgamma-producing), cross-reactive CD8(+) T cells, and vaccinated HBs-tg mice showed reduced antigenemia. Hence, vaccination with natural HBsAg variants from different HBV sero/genotypes can prime cross-reactive, specific CD8(+) T cell immunity that breaks tolerance to HBsAg.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14635042     DOI: 10.1002/eji.200324403

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.

Authors:  Melissa A Cobleigh; Linda Buonocore; Susan L Uprichard; John K Rose; Michael D Robek
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  Different sources of "help" facilitate the antibody response to hepatitis D virus delta antigen.

Authors:  Peter Seizer; Petra Riedl; Jörg Reimann; Reinhold Schirmbeck
Journal:  J Mol Med (Berl)       Date:  2004-11-10       Impact factor: 4.599

3.  A new vaccine escape mutant of hepatitis B virus causes occult infection.

Authors:  Qing Ye; Shi-Qiang Shang; Wei Li
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.

Authors:  Melissa A Cobleigh; Clinton Bradfield; Yuanjie Liu; Anand Mehta; Michael D Robek
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

5.  Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization.

Authors:  Yuan Hong; Yibing Peng; Haiyan Xiao; Michael Mi; David Munn; Yukai He
Journal:  J Immunol       Date:  2012-04-13       Impact factor: 5.422

6.  A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice.

Authors:  Melissa A Cobleigh; Xin Wei; Michael D Robek
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

7.  Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.

Authors:  Tracy D Reynolds; Linda Buonocore; Nina F Rose; John K Rose; Michael D Robek
Journal:  J Virol       Date:  2015-08-05       Impact factor: 5.103

8.  Praziquantel facilitates IFN-γ-producing CD8+ T cells (Tc1) and IL-17-producing CD8+ T cells (Tc17) responses to DNA vaccination in mice.

Authors:  Qiang Zou; Xin Yao; Jin Feng; Zhinan Yin; Richard Flavell; Yanxin Hu; Guoxing Zheng; Jin Jin; Youmin Kang; Bing Wu; Xiaoxuan Liang; Congcong Feng; Hu Liu; Weiyi Li; Xianzheng Wang; Yumei Wen; Bin Wang
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

Review 9.  Design of therapeutic vaccines: hepatitis B as an example.

Authors:  Sarah Kutscher; Tanja Bauer; Claudia Dembek; Martin Sprinzl; Ulrike Protzer
Journal:  Microb Biotechnol       Date:  2011-09-29       Impact factor: 5.813

10.  Discovery and Selection of Hepatitis B Virus-Derived T Cell Epitopes for Global Immunotherapy Based on Viral Indispensability, Conservation, and HLA-Binding Strength.

Authors:  Monique T A de Beijer; Diahann T S L Jansen; Yingying Dou; Wim J E van Esch; Juk Yee Mok; Mariëlle J P Maas; Giso Brasser; Robert A de Man; Andrea M Woltman; Sonja I Buschow
Journal:  J Virol       Date:  2020-03-17       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.